Infectious disease immunotherapies – An update: Revisiting an age-old adage in times of COVID-19
This review article tries to bring together the important active and passive immunotherapeutic modalities currently under consideration for COVID-19 disease. The basis of immunotherapy is based on use of naturally occurring agents or drugs to modify the body's immune response to certain antigen...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2021-01-01
|
| Series: | Journal of Marine Medical Society |
| Subjects: | |
| Online Access: | http://www.marinemedicalsociety.in/article.asp?issn=0975-3605;year=2021;volume=23;issue=1;spage=10;epage=15;aulast=Lall |
| _version_ | 1818454331458846720 |
|---|---|
| author | Mahima Lall Suyash Singh Amar Atal Anuj Singhal |
| author_facet | Mahima Lall Suyash Singh Amar Atal Anuj Singhal |
| author_sort | Mahima Lall |
| collection | DOAJ |
| description | This review article tries to bring together the important active and passive immunotherapeutic modalities currently under consideration for COVID-19 disease. The basis of immunotherapy is based on use of naturally occurring agents or drugs to modify the body's immune response to certain antigens, the host immune system competent to successfully target and eliminate the infectious agent, without altering the normal physiology. Pubmed was screened for studies using key words; COVID-19, Convalescent plasma therapy, Immunotherapy, Clinical trials. We identified 537 studies through database searches. After reviewing the title and abstracts, we excluded 452 studies that were not relevant, leaving 85 studies for full-text evaluation. Of these, 53 studies fulfilling predefined inclusion/exclusion criteria were finally included. This study found that the common immunotherapies which were used in COVID-19 pandemic times were plasma therapy, T-reg based therapy, tocilizumab, hydroxychloroquine, dexamethasone, and baricitinib. |
| first_indexed | 2024-12-14T21:53:11Z |
| format | Article |
| id | doaj.art-3898946ad848472787963e558f7e787f |
| institution | Directory Open Access Journal |
| issn | 0975-3605 |
| language | English |
| last_indexed | 2024-12-14T21:53:11Z |
| publishDate | 2021-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Journal of Marine Medical Society |
| spelling | doaj.art-3898946ad848472787963e558f7e787f2022-12-21T22:46:11ZengWolters Kluwer Medknow PublicationsJournal of Marine Medical Society0975-36052021-01-01231101510.4103/jmms.jmms_126_20Infectious disease immunotherapies – An update: Revisiting an age-old adage in times of COVID-19Mahima LallSuyash SinghAmar AtalAnuj SinghalThis review article tries to bring together the important active and passive immunotherapeutic modalities currently under consideration for COVID-19 disease. The basis of immunotherapy is based on use of naturally occurring agents or drugs to modify the body's immune response to certain antigens, the host immune system competent to successfully target and eliminate the infectious agent, without altering the normal physiology. Pubmed was screened for studies using key words; COVID-19, Convalescent plasma therapy, Immunotherapy, Clinical trials. We identified 537 studies through database searches. After reviewing the title and abstracts, we excluded 452 studies that were not relevant, leaving 85 studies for full-text evaluation. Of these, 53 studies fulfilling predefined inclusion/exclusion criteria were finally included. This study found that the common immunotherapies which were used in COVID-19 pandemic times were plasma therapy, T-reg based therapy, tocilizumab, hydroxychloroquine, dexamethasone, and baricitinib.http://www.marinemedicalsociety.in/article.asp?issn=0975-3605;year=2021;volume=23;issue=1;spage=10;epage=15;aulast=Lallclinical trialsconvalescent plasma therapycovid-19immunotherapy |
| spellingShingle | Mahima Lall Suyash Singh Amar Atal Anuj Singhal Infectious disease immunotherapies – An update: Revisiting an age-old adage in times of COVID-19 Journal of Marine Medical Society clinical trials convalescent plasma therapy covid-19 immunotherapy |
| title | Infectious disease immunotherapies – An update: Revisiting an age-old adage in times of COVID-19 |
| title_full | Infectious disease immunotherapies – An update: Revisiting an age-old adage in times of COVID-19 |
| title_fullStr | Infectious disease immunotherapies – An update: Revisiting an age-old adage in times of COVID-19 |
| title_full_unstemmed | Infectious disease immunotherapies – An update: Revisiting an age-old adage in times of COVID-19 |
| title_short | Infectious disease immunotherapies – An update: Revisiting an age-old adage in times of COVID-19 |
| title_sort | infectious disease immunotherapies an update revisiting an age old adage in times of covid 19 |
| topic | clinical trials convalescent plasma therapy covid-19 immunotherapy |
| url | http://www.marinemedicalsociety.in/article.asp?issn=0975-3605;year=2021;volume=23;issue=1;spage=10;epage=15;aulast=Lall |
| work_keys_str_mv | AT mahimalall infectiousdiseaseimmunotherapiesanupdaterevisitinganageoldadageintimesofcovid19 AT suyashsingh infectiousdiseaseimmunotherapiesanupdaterevisitinganageoldadageintimesofcovid19 AT amaratal infectiousdiseaseimmunotherapiesanupdaterevisitinganageoldadageintimesofcovid19 AT anujsinghal infectiousdiseaseimmunotherapiesanupdaterevisitinganageoldadageintimesofcovid19 |